The Early Detection Research Network has helped six cancer diagnostic tests achieve FDA-approval.
- One combined test to assess the risk for hepatocellular cancer: DCP and AFP-L3
- Two tests help to determine the need for prostate biopsies: %[2]proPSA and PCA3
- Three tests help to predict risk of ovarian cancer in women with a pelvic mass: OVA1TM, OveraTM and a combined test known as ROMATM with CA125 and HE4